ESMO 2018 - Results from #20

Viewing 21-40 of 96 articles

ESMO 2018: KEYNOTE-427 Cohort A: Pembrolizumab Monotherapy as First-line Therapy in advanced clear cell Renal Cell Carcinoma (ccRCC)

ESMO 2018: Activity of Cabozantinib After PD-1/PD-L1 Immune Checkpoint Blockade In Metastatic Clear Cell Renal Cell Carcinoma

ESMO 2018: COSMIC-021, Phase Ib Study of Cabozantinib in Combination with Atezolizumab and Potent Natural Killer, Myeloid Blood Cell Remodeling by Cabozantinib

ESMO 2018: Clinical Experience of 100 Consecutive Patients Treated with Lu-177-labeled PSMA-I&T Radioligand Therapy for mCRPC

ESMO 2018: ABACUS, A phase II Study Investigating the Safety and Efficacy of Neoadjuvant Atezolizumab in Muscle Invasive Bladder Cancer

ESMO 2018: What is New in Metastatic Castration Resistant Prostate Cancer?

ESMO 2018: The Prognostic Value of the Proportion and Subtype Patterns of Intraductal Carcinoma with De Novo Metastatic Prostate Cancer: A Propensity Score Matching Study

ESMO 2018: STAMPEDE - Effects of Abiraterone Acetate plus Prednisone/Prednisolone in High and Low Risk Metastatic Hormone Sensitive Prostate Cancer

ESMO 2018: Avelumab + Axitinib vs Sunitinib for the Management of Advanced Renal Cell Carcinoma - JAVELIN Renal 101

ESMO 2018: Statin Use and Outcome in Metastatic Castration-Resistant Prostate Cancer Patients Treated in the TROPIC Trial

ESMO 2018: Survival Results from STAMPEDE, Local Radiotherapy Improves Survival in Metastatic Prostate Cancer with Low Disease Burden

ESMO 2018: Oligometastatic Disease - The Critical Need of a Multidisciplinary Approach for the Treatment of Prostate Cancer

ESMO 2018: Effects of Abiraterone Acetate plus Prednisone/Prednisolone in High and Low Risk Metastatic Hormone Sensitive Prostate Cancer

ESMO 2018: Update on Diagnosis and Treatment of Localized Prostate Cancer

ESMO 2018: Radiotherapy to the Primary Tumour for Men with Newly-Diagnosed Metastatic Prostate Cancer: Survival Results from STAMPEDE

ESMO 2018: JAVELIN Renal 101: A Randomized, Phase 3 Study of Avelumab + Axitinib vs Sunitinib as First-Line Treatment of Advanced Renal Cell Carcinoma

Local Radiotherapy Improves Survival in Metastatic Prostate Cancer with Low Disease Burden

Avelumab Plus Axitinib Significantly Improve Progression-Free Survival in Untreated Renal Cell Carcinoma

ESMO 2018: Efficacy and Safety Results of GETUG, Axitinib in Metastatic Papillary Renal Cancer

ESMO 2018: Tobacco Control: Saving Lives and Driving Development

1
2
3
4
5